Oragenics appoints CFO Janet Huffman as Interim CEO; Preferred conversion cancels $2.35M liquidation preference

ORAGENICS INC

J. Michael Redmond terminated as Interim CEO/President effective Dec 16, 2024; CFO Janet Huffman appointed as new Interim CEO and President.
Shareholders approved increasing 2021 Equity Incentive Plan by 2M shares to total 3,166,667 shares.
All remaining Series A (5,417,000) and Series B (4,050,000) preferred shares converted to ~22,000 common shares, eliminating $2.35M liquidation preference.
Directors re-elected: Charles Pope, Frederick Telling, Alan Dunton, Robert Koski, John Gandolfo, Bruce Cassidy.
Advisory vote on executive compensation passed with 1,931,906 for vs 365,871 against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.